Cancer Immunotherapy Market by Type (Monoclonal Antibodies, Cancer Vaccines, Check Point Inhibitors & Immunomodulators), Application (Lung, Breast, Colorectal, Melanoma, Prostate, Head & Neck), End User (Hospital and Clinics) - Global Forecast to 2021

Table of Contents

1 INTRODUCTION 14

1.1 OBJECTIVES OF THE STUDY 14
1.2 MARKET DEFINITION 14
1.3 MARKETS COVERED 15
1.3.1 YEARS CONSIDERED FOR THE STUDY 16
1.4 CURRENCY 17
1.5 STAKEHOLDERS 17

2 RESEARCH METHODOLOGY 18

2.1 MARKET SIZE ESTIMATION 19
2.2 MARKET BREAKDOWN AND DATA TRIANGULATION 22
2.3 MARKET SHARE ESTIMATION 23
2.3.1 KEY DATA FROM SECONDARY SOURCES 23
2.3.2 KEY DATA FROM PRIMARY SOURCES 24
2.4 ASSUMPTIONS FOR THE STUDY 24

3 EXECUTIVE SUMMARY 25

3.1 INTRODUCTION 25
3.2 CURRENT SCENARIO 25
3.3 FUTURE OUTLOOK 26

4 PREMIUM INSIGHTS 30

4.1 LUCRATIVE OPPORTUNITIES IN THE CANCER IMMUNOTHERAPY MARKET 30

5 MARKET OVERVIEW 34

5.1 INTRODUCTION 35
5.1.1 DRIVERS 36
5.1.1.1 Rise in incidence rate of cancer worldwide 36
5.1.1.2 Increase in adoption of immunotherapy over other treatment options 36
5.1.1.3 Development of bioinformatics tools are enhancing drug development process 37
5.1.2 RESTRAINTS 37
5.1.2.1 High cost of treatment 37
5.1.3 OPPORTUNITIES 37
5.1.3.1 Increase in clinical trials against several types of cancers in immunotherapy 37
5.1.3.2 High growth projections in the developing countries 38
5.1.4 CHALLENGES 38
5.1.4.1 Availability of Limited funds to initiate clinical trials 38
5.1.4.2 Complexity of cancer may limit the immune response 38
5.2 OVERVIEW OF GLOBAL CANCER IMMUNOTHERAPY FUNDING 39

6 INDUSTRY TRENDS 42

6.1 GLOBAL TRENDS IN CANCER IMMUNOTHERAPY MARKET 42
6.1.1 OPDIVO (NIOLUMAB) AND KEYTRUDA (PEMBROLIZUMAB) FDA APPROVAL IN U.S. INCREASES HOPE AMONGST LUNG CANCER PATIENTS 42
6.1.2 COMBINATION IMMUNOTHERAPY POTENTIAL WAY TO TREAT MELANOMA 42
6.1.3 U.S. CANCER IMMUNOTHERAPY RESEARCH COMMUNITY BUILDS HOPE TO COMBAT CANCER BY 2020 42
6.1.4 U.K. SCIENTISTS PROJECT A CHANGE IN THE MEANS OF TREATMENT FOR CANCER WITH QUALITY THERAPIES 43
6.1.5 WORLD IS MOVING TOWARD PERSONALIZED IMMUNOTHERAPY 43
6.1.6 A COMBINATION OF MODERN IMMUNOTHERAPY AND TRADITIONAL CHINESE MEDICINES CONTINUES TO INCREASE SURVIVAL RATE OF PATIENTS IN CHINA 43
6.2 PRICING VARIATIONS IN GLOBAL CANCER IMMUNOTHERAPY MARKET 44
6.3 SMALL PLAYERS GETTING TOGETHER TO MAKE LONG TERM IMPACT IN CANCER IMMUNOTHERAPY MARKET 45
6.4 ATTRACTIONS FOR PHARMACEUTICAL INDUSTRY 46
6.5 HEAT MAP FOR VARIATIONS IN CANCER IMMUNOTHERAPY FOR DIFFERENT TYPES OF CANCERS 47
6.5.1 BREAST CANCER 47
6.5.2 LUNG CANCER 48
6.5.3 MULTIPLE MYELOMA 49
6.5.4 LYMPHOMA 50

7 CANCER IMMUNOTHERAPY MARKET, BY PRODUCT TYPE 53

7.1 INTRODUCTION 54
7.2 MONOCLONAL ANTIBODIES 55
7.2.1 NAKED MONOCLONAL ANTIBODIES 57
7.2.2 CONJUGATED MONOCLONAL ANTIBODIES 58
7.2.3 BISPECIFIC MONOCLONAL ANTIBODIES 59
7.3 VACCINES 59
7.3.1 PROPHYLACTIC VACCINES 61
7.3.2 THERAPEUTIC VACCINES 62
7.4 CHECK POINT INHIBITORS 63
7.4.1 CYTOTOXIC T-LYMPHOCYTE-ASSOCIATED PROTEIN-4 (CTLA-4) 64
7.4.2 PROGRAMMED DEATH 1 (PD-1) AND PROGRAMMED DEATH LIGAND 1 (PD-L1) 65
7.5 CELL THERAPIES 66
7.5.1 CHIMERIC ANTIGEN RECEPTOR (CAR) T CELL THERAPY 66
7.5.2 DENDRITIC CELLS 66
7.6 IMMUNOMODULATORS 67
7.6.1 GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR
(GM-CSF & G-CSF) 69
7.6.2 INTERFERONS (IFN) 69
7.6.3 INTERLEUKINS (IL) 70
7.6.4 ONCOLYTIC VIRUS 71
7.6.4.1 Immunotherapy 71
7.6.4.1 Immunity as an obstacle 71
7.6.4.2 Immunity as an ally 71
7.6.4.3 Approved Products & Clinical Trails 71

8 CANCER IMMUNOTHERAPY MARKET, BY APPLICATION 72

8.1 INTRODUCTION 73
8.2 LUNG CANCER 74
8.3 BREAST CANCER 75
8.4 MULTIPLE MYELOMA 77
8.5 COLORECTAL CANCER 78
8.6 HEAD & NECK CANCER 79
8.7 PROSTATE CANCER 80
8.8 MELANOMA 81
8.9 OTHER CANCER TYPES 83

9 CANCER IMMUNOTHERAPY MARKET, BY END USER 84

9.1 INTRODUCTION 85
9.2 HOSPITAL 86
9.3 CLINICS AND OTHERS 87

10 CANCER IMMUNOTHERAPY MARKET, BY REGION 88

10.1 INTRODUCTION 89
10.2 NORTH AMERICA 91
10.3 EUROPE 94
10.4 ASIA-PACIFIC 96
10.5 REST OF THE WORLD (ROW) 99

11 COMPETITIVE LANDSCAPE 100

11.1 OVERVIEW 101
11.2 MARKET SHARE ANALYSIS 102
11.3 COMPETITIVE SITUATION AND TRENDS 103
11.3.1 APPROVALS 103
11.3.2 AGREEMENTS, PARTNERSHIPS, AND COLLABORATIONS 105
11.3.3 ACQUISITIONS 107
11.3.4 EXPANSIONS 108
11.3.5 OTHER DEVELOPMENTS 108

12 COMPANY PROFILE 109

(Business Overview, Products & Services, Key Insights, Recent Developments, SWOT Analysis, Ratio Analysis, MnM View)*
12.1 AMGEN INC. 109
12.2 ASTRAZENECA 112
12.3 BAYER AG 114
12.4 BRISTOL-MYERS SQUIBB 117
12.5 ELI LILLY AND COMPANY 120
12.6 JANSSEN GLOBAL SERVICES, LLC (JOHNSON AND JOHNSON) 123
12.7 MERCK 126
12.8 NOVARTIS 129
12.9 PFIZER 132
12.10 F. HOFFMANN-LA ROCHE LTD 134
*Details on Business Overview, Products & Services, Key Insights, Recent Developments, SWOT Analysis, MnM View might not be captured in case of unlisted companies.
13 APPENDIX 137

LIST OF TABLES

TABLE 1 OVERVIEW OF FUNDING PATTERN IN DIFFERENT TYPES OF CANCER BY NIH, U.S., 2012–2017 (USD MILLION) 39
TABLE 2 OVERVIEW OF KEY FUNDING IN CANCER IMMUNOTHERAPY MARKET, 2016 40
TABLE 3 CONVENTIONAL CANCER THERAPY VERSUS CANCER IMMUNOTHERAPY 41
TABLE 4 CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT TYPE,
2014–2021 (USD MILLION) 55
TABLE 5 CANCER MONOCLONAL ANTIBODIES MARKET SIZE, BY SUBTYPE,
2014–2021 (USD MILLION) 56
TABLE 6 CANCER MONOCLONAL ANTIBODIES MARKET, BY REGION,
2014–2021 (USD MILLION) 57
TABLE 7 NAKED MONOCLONAL ANTIBODIES MARKET, BY REGION,
2014–2021 (USD MILLION) 58
TABLE 8 CONJUGATED MONOCLONAL ANTIBODIES MARKET, BY REGION,
2014–2021 (USD MILLION) 58
TABLE 9 BISPECIFIC MONOCLONAL ANTIBODIES MARKET SIZE, BY REGION,
2014–2021 (USD MILLION) 59
TABLE 10 VACCINES MARKET, BY SUBTYPE, 2014–2021 (USD MILLION) 60
TABLE 11 VACCINES MARKET, BY REGION, 2014–2021 (USD MILLION) 61
TABLE 12 PROPHYLACTIC VACCINES MARKET SIZE, 2014–2021 (USD MILLION) 62
TABLE 13 THERAPEUTIC VACCINES MARKET, BY REGION, 2014–2021 (USD MILLION) 62
TABLE 14 CHECKPOINT INHIBITORS MARKET SIZE, BY SUBTYPE, 2014–2021 (USD MILLION) 63
TABLE 15 CHECKPOINT INHIBITORS MARKET, BY REGION, 2014–2021 (USD MILLION) 64
TABLE 16 CYTOXIC T-LYMPHOCYTE MARKET SIZE, BY REGION, 2014–2021 (USD MILLION) 65
TABLE 17 CYTOXIC T-LYMPHOCYTE MARKET SIZE, BY REGION, 2014–2021 (USD MILLION) 65
TABLE 18 IMMUNOMODULATORS MARKET SIZE, BY SUBTYPE, 2014–2021 (USD MILLION) 67
TABLE 19 IMMUNOMODULATORS MARKET SIZE, BY REGION, 2014–2021 (USD MILLION) 68
TABLE 20 GRANULOCYTE/MACROPHAGE COLONY-STIMULATING FACTOR (GM-CSF) MARKET SIZE, BY REGION, 2014–2021 (USD MILLION) 69
TABLE 21 INTERFERONS MARKET SIZE, BY REGION, 2014–2021 (USD MILLION) 70
TABLE 22 INTERLEUKINS MARKET SIZE, BY REGION, 2014–2021 (USD MILLION) 70
TABLE 23 CANCER IMMUNOTHERAPY MARKET SIZE, BY APPLICATION, 2014–2021 (USD MILLION) 74
TABLE 24 LUNG CANCER MARKET SIZE, BY REGION, 2014–2021 (USD MILLION) 75
TABLE 25 BREAST CANCER MARKET SIZE, BY REGION, 2014–2021 (USD MILLION) 76
TABLE 26 MULTIPLE MYELOMA MARKET SIZE, BY REGION, 2014–2021 (USD MILLION) 77
TABLE 27 COLORECTAL CANCER MARKET SIZE, BY REGION, 2014–2021 (USD MILLION) 78
TABLE 28 HEAD & NECK CANCER MARKET SIZE, BY REGION, 2014–2021 (USD MILLION) 80
TABLE 29 PROSTATE CANCER MARKET SIZE, BY REGION, 2014–2021 (USD MILLION) 81
TABLE 30 MELANOMA MARKET SIZE, BY REGION, 2014–2021 (USD MILLION) 82
TABLE 31 OTHER TYPES OF CANCER MARKET SIZE, BY REGION, 2014–2021 (USD MILLION) 83
TABLE 32 CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER,
2014–2021 (USD MILLION) 85
TABLE 33 HOSPITALS MARKET SIZE, BY REGION, 2014–2021 (USD MILLION) 86
TABLE 34 CLINICS AND OTHERS MARKET SIZE, BY REGION, 2014–2021 (USD MILLION) 87
TABLE 35 CANCER IMMUNOTHERAPY MARKET SIZE, BY REGION, 2014–2021 (USD MILLION) 90
TABLE 36 NORTH AMERICA: CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT TYPE, 2014–2021 (USD MILLION) 93
TABLE 37 EUROPE: CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT TYPE,
2014–2021 (USD MILLION) 95
TABLE 38 ASIA-PACIFIC: CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT TYPE, 2014–2021 (USD MILLION) 98
TABLE 39 ROW: CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT TYPE,
2014–2021 (USD MILLION) 99
TABLE 40 APPROVALS, 2013–2016 103
TABLE 41 AGREEMENTS, PARTNERSHIPS, AND COLLABORATIONS, 2013–2016 105
TABLE 42 ACQUISITIONS, 2013–2016 107
TABLE 43 EXPANSIONS, 2013–2016 108

LIST OF FIGURES

FIGURE 1 CLASSIFICATION OF CANCER IMMUNOTHERAPY 15
FIGURE 2 RESEARCH DESIGN 18
FIGURE 3 MARKET SIZE ESTIMATION METHODOLOGY: BOTTOM-UP APPROACH 20
FIGURE 4 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH 20
FIGURE 5 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY, DESIGNATION, AND REGION 21
FIGURE 6 DATA TRIANGULATION METHODOLOGY 22
FIGURE 7 THE MONOCLONAL ANTIBODY SEGMENT IS EXPECTED TO LEAD THE GLOBAL CANCER IMMUNOTHERAPY MARKET DURING THE FORECAST PERIOD 26
FIGURE 8 THE LUNG CANCER SEGMENT TO LEAD THE GLOBAL CANCER IMMUNOTHERAPY MARKET IN 2016 27
FIGURE 9 HOSPITALS ARE MAJOR END USERS OF THE GLOBAL CANCER IMMUNOTHERAPY MARKET 27
FIGURE 10 NORTH AMERICA LED THE GLOBAL CANCER IMMUNOTHERAPY MARKET IN 2015 28
FIGURE 11 FUTURE OF CANCER IMMUNOTHERAPEUTICS 29
FIGURE 12 GLOBAL CANCER IMMUNOTHERAPY MARKET TO WITNESS HIGH GROWTH DURING THE FORECAST PERIOD 30
FIGURE 13 LUNG CANCER APPLICATION DOMINATED THE GLOBAL CANCER IMMUNOTHERAPY MARKET, 2016 31
FIGURE 14 ASIA-PACIFIC TO WITNESS THE FASTEST GROWTH DURING THE FORECAST PERIOD 32
FIGURE 15 LUNG CANCER TO WITNESS THE FASTEST GROWTH DURING THE FORECAST PERIOD IN THE CANCER IMMUNOTHERAPY MARKET 33
FIGURE 16 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 35
FIGURE 17 POPULATION FORECASTS FOR ALL CANCERS EXCLUDING NON-MELANOMA SKIN CANCER, 2012 VS. 2020 36
FIGURE 18 PRICING TREND OF IMBRUVICA ACROSS MAJOR PHARMACEUTICAL MARKET
IN 2016 44
FIGURE 19 HEAT MAP SHOWING VARIATIONS IN IMMUNOTHERAPY DRUGS USED FOR BREAST CANCER 47
FIGURE 20 ANNUAL COST OF BREAST CANCER IMMUNOTHERAPY, 2016 48
FIGURE 21 HEAT MAP SHOWING VARIATIONS IN IMMUNOTHERAPY DRUGS USED FOR LUNG CANCER 48
FIGURE 22 ANNUAL COST OF LUNG CANCER IMMUNOTHERAPY, 2016 49
FIGURE 23 HEAT MAP SHOWING VARIATIONS IN IMMUNOTHERAPY DRUGS USED FOR MULTIPLE MYELOMA 49
FIGURE 24 ANNUAL COST OF MULTIPLE MYELOMA IMMUNOTHERAPY, 2016 50
FIGURE 25 HEAT MAP SHOWING VARIATIONS IN IMMUNOTHERAPY DRUGS USED FOR LYMPHOMA 50
FIGURE 26 ANNUAL COST OF LYMPHOMA IMMUNOTHERAPY, 2016 51
FIGURE 27 CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT TYPE 54
FIGURE 28 MONOCLONAL ANTIBODIES SEGMENT TO DOMINATE THE CANCER IMMUNOTHERAPY MARKET SIZE IN 2016 55
FIGURE 29 NAKED MONOCLONAL ANTIBODIES TO ACCOUNT FOR THE LARGEST
SHARE IN 2016 56
FIGURE 30 NORTH AMERICA TO ACCOUNT FOR THE LARGEST SHARE OF THE CANCER MONOCLONAL ANTIBODIES MARKET IN 2016 57
FIGURE 31 VACCINES MARKET SIZE, BY SUBTYPE, 2016–2021 (USD MILLION) 60
FIGURE 32 ASIA-PACIFIC EXPECTED TO BE THE FASTEST-GROWING REGIONAL SEGMENT OF THE VACCINES MARKET 61
FIGURE 33 PROGRAMMED DEATH 1(PD-1) IS EXPECTED TO BE THE FASTEST-GROWING SEGMENT OF THE CHECK POINT INHIBITORS MARKET 63
FIGURE 34 ROW IS EXPECTED TO ACCOUNT THE FASTEST-GROWING REGIONAL SEGMENT OF THE CHECKPOINT INHIBITORS MARKET 64
FIGURE 35 GM-CSF & G-CSF SEGMENT IS EXPECTED TO DOMINATE THE IMMUNOMODULATORS MARKET IN 2016 67
FIGURE 36 NORTH AMERICA IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE IN THE IMMUNOMODULATORS MARKET THROUGH 2021 68
FIGURE 37 CANCER IMMUNOTHERAPY MARKET, BY APPLICATION 73
FIGURE 38 LUNG CANCER SEGMENT LEADS THE CANCER IMMUNOTHERAPY MARKET
SIZE IN 2016 73
FIGURE 39 NORTH AMERICA ACCOUNTS FOR THE LARGEST SHARE OF THE LUNG CANCER IMMUNOTHERAPY MARKET IN 2016 75
FIGURE 40 NORTH AMERICA ACCOUNTS FOR THE LARGEST SHARE OF THE CANCER IMMUNOTHERAPY MARKET FOR BREAST CANCER IN 2016 76
FIGURE 41 NORTH AMERICA ACCOUNTS FOR THE LARGEST SHARE OF THE CANCER IMMUNOTHERAPY MARKET FOR MULTIPLE MYELOMA IN 2016 77
FIGURE 42 NORTH AMERICA ACCOUNTS FOR THE LARGEST SHARE OF THE CANCER IMMUNOTHERAPY MARKET FOR COLORECTAL CANCER IN 2016 78
FIGURE 43 NORTH AMERICA ESTIMATED TO ACCOUNT FOR THE LARGEST SHARE OF THE IMMUNOTHERAPY MARKET FOR HEAD & NECK CANCER IN 2016 79
FIGURE 44 NORTH AMERICA ESTIMATED TO DOMINATE THE IMMUNOTHERAPY MARKET FOR PROSTATE CANCER IN 2016 80
FIGURE 45 NORTH AMERICA IS PROJECTED TO BE THE FASTEST-GROWING REGION IN THE CANCER IMMUNOTHERAPY MARKET FOR MELANOMA DURING THE FORECAST PERIOD 82
FIGURE 46 ASIA-PACIFIC IS PROJECTED TO BE THE FASTEST-GROWING REGION IN THE IMMUNOTHERAPY MARKET FOR OTHER CANCER TYPES, 2016-2021 83
FIGURE 47 CANCER IMMUNOTHERAPY MARKET, BY END USER,
2016 VS. 2021 (USD MILLION) 85
FIGURE 48 HOSPITALS MARKET SIZE, 2016 VS. 2021, BY REGION (USD MILLION) 86
FIGURE 49 CLINICS AND OTHERS MARKET SIZE, BY REGION, 2016 VS. 2021 (USD MILLION) 87
FIGURE 50 GEOGRAPHIC SNAPSHOT: ASIA-PACIFIC IS PROJECTED TO BE THE FASTEST-GROWING REGION DURING THE FORECAST PERIOD 89
FIGURE 51 CHECKPOINT INHIBITORS SEGMENT IS PROJECTED TO GROW AT THE HIGHEST RATE FROM 2016 TO 2021 90
FIGURE 52 NORTH AMERICA: CANCER IMMUNOTHERAPY MARKET SNAPSHOT, 2016 92
FIGURE 53 THE CHECK POINT INHIBITORS IS PROJECTED TO BE THE FASTEST-GROWING MARKET IN NORTH AMERICA DURING THE FORECAST PERIOD 93
FIGURE 54 MONOCLONAL ANTIBODIES SEGMENT IS PROJECTED TO DOMINATE THE CANCER IMMUNOTHERAPY MARKET IN EUROPE TILL 2021 95
FIGURE 55 ASIA-PACIFIC: CANCER IMMUNOTHERAPY MARKET SNAPSHOT, 2016 97
FIGURE 56 CHECKPOINT INHIBITORS SEGMENT IS EXPECTED TO LEAD THE CANCER IMMUNOTHERAPY MARKET IN THE ROW REGION TILL 2021 99
FIGURE 57 COMPANIES ADOPTED APPROVALS AS THEIR KEY GROWTH STRATEGY OVER THE LAST THREE YEARS 101
FIGURE 58 GLOBAL CANCER IMMUNOTHERAPY MARKET SHARE, BY KEY PLAYER, 2015 102
FIGURE 59 APPROVALS: THE KEY GROWTH STRATEGY ADOPTED BY MARKET PLAYERS FROM 2013 TO 2015 103
FIGURE 60 AMGEN: COMPANY SNAPSHOT 109
FIGURE 61 ASTRAZENECA: COMPANY SNAPSHOT 112
FIGURE 62 BAYER AG: COMPANY SNAPSHOT 114
FIGURE 63 BRISTOL-MYERS SQUIBB: COMPANY SNAPSHOT 117
FIGURE 64 ELI LILLY AND COMPANY: COMPANY SNAPSHOT 120
FIGURE 65 JANSSEN GLOBAL SERVICES, LLC: COMPANY SNAPSHOT 123
FIGURE 66 MERCK: COMPANY SNAPSHOT 126
FIGURE 67 NOVARTIS; COMPANY SNAPSHOT 129
FIGURE 68 PFIZER : COMPANY SNAPSHOT 132
FIGURE 69 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT 134

当レポートのプレスリリースは発行されておりません。